Unbiased Analysis of Today's Healthcare Issues
If you were a drug manufacturer, you naturally would want to focus your research on more common, highly prevalent diseases. If there are more patients with the disease, that means more drugs that can be sold. In recent years, however, the number of so-called “orphan drugs” has increased. In the 1970s, only 10 orphan drugs…
That is the topic of a recent paper by Augustovski et al. (2021). The authors conduct a targeted literature review of previous diagnostics value frameworks in other countries. A full list of these articles is below. Then the researchers pool the criteria and created a proposed value framework. A panel of experts was then met…
Value frameworks are all the rage of late. But are payers really using them? According to my colleague Jeremy Schafer, the answer is yes. From an article in Drug Topics: “Value assessment may become more important as the health-care market shifts to outcomes and value-based reimbursement models,” said Jeremy Schafer, PharmD, MBA, Senior Vice President…
Along with co-authors Jeremy Schafer and Dominic Galante, I have a new paper out in JMCP this month. The abstract is below, but do read the whole piece here. BACKGROUND: Organizations such as the National Comprehensive Cancer Network, American Society of Clinical Oncology, Institute for Clinical and Economic Review, and Memorial Sloan Kettering have created…
The Healthcare Economist has been published in this month’s edition of Pharmaceutical Commerce. The article, titled Value frameworks are here: What to do about them?, provides a brief overview of the existing value frameworks and describes what steps life sciences company can take to evaluate the value of their innovations. Value frameworks are here: What to do about…
That is the abbreviated title of a new commentary on the Forbes blog that I wrote with Tomas Philipson. The full article is HERE. An excerpt is below. New value frameworks in health care have emerged due to increasing cost pressures. Although value frameworks can be useful tools, they should be used to complement the…
In recent years, a number of organizations have developed value frameworks to assess new treatments. These organizations include the Institute for Clinical and Economic Review (ICER), Memorial Sloan Kettering Memorial Cancer Center (Drug Abacus), American Society for Clinical Oncologists (ASCO), National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (Magnitude of Clinical Benefit Scale).…